Clinical Trials Browser

OTHER × Lung Neoplasms × sintilimab × Clear all

NCT03872661 2024-12-06

NIBCUN

Phase 2 Recruiting

Lung Neoplasms

NCT04973293 2024-11-19

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06688656 2024-11-14

Peri-E

Phase 2 Not yet recruiting

Lung Neoplasms

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT06267144 2024-02-20

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

Phase 2 Completed

Lung Neoplasms

NCT04513301 2020-08-14

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

Phase 2 Unknown

Lung Neoplasms

NCT04486287 2020-07-24

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

Phase 2 Unknown

Lung Neoplasms

NCT04189094 2019-12-06

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Phase 2 Unknown

Lung Neoplasms

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Phase 2 Unknown

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms